Amyloid β-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists

Journal of Alzheimer's Disease

Volumn 4, Issue 3, 2002, Pages 193-201

  Butterfield, D Allan ^a   Griffin, Sue ^a   Munch, Gerald ^a   Pasinetti, Giulio Maria ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALZHEIMER DISEASE VACCINE; AMYLOID; AMYLOID BETA PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLUTAMIC ACID; INTERLEUKIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE PHASE RESPONSE; ALZHEIMER DISEASE; CELL ACTIVATION; DISEASE COURSE; GLIA CELL; HUMAN; INFLAMMATION; MICROGLIA; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0036592636     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2002-4309     Document Type: Review

References (94)

1. Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies
2. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
3. Advanced protein glycosylation in diabetes and aging
4. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats
5. B-amyloid-associated free radical oxidative stress and neurotoxicity: Implications for Alzheimer's disease
6. Review: Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contributes to neuronal death
7. Evidence of oxidative damage in Alzheimer's disease brain: Central role of amyloid beta-peptide
8. Oxidatively-induced structural alteration of glutamine synthetase assessed by analysis of spin labeled incorporation kinetics: Relevance to Alzheimer's disase
9. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins
10. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress
11. Protein oxidation processes in aging brain
12. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; Its possible role in the febrile response
13. Expression of the Alzheimer amyloid-promoting factors α1 antichymotrypsin and apolipoprotein E is induced in astrocytes by IL-1
14. Glycation and microglial reaction in lesions of Alzheimers disease
15. Association of an interleukin1 polymorphism with Alzheimer's disease
16. Oxidative regulation of fatty acid-induced tau polymerization
17. Interleukin-1 regulates synthesis of amyloid beta precursor mRNA in human endothelial cells
18. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
19. Interleukin-1 expression in different plaque types in Alzheimer's disease
20. Association of early onset Alzheimer's disease with an interleukin-1α gene polymorphism
21. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type
22. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia
23. Beta-amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: Implications for Alzheimer's disease
24. Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures
25. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation
26. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
27. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease
28. Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT)
29. App(SW) transgenic mice develop age-related A-beta deposits and neuropil abnormalities, but no neuronal loss in CA 1
30. Fibrillar Alzheimer's amyloid peptide Abeta(1-42) stimulates low density lipoprotein binding and cell association, free radical production and cell cytotoxicity in PC12 cells
31. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
32. Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons
33. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
34. NMDA-dependent superoxide production and neurotoxicity
35. Apoliprotein E knock-out synaptosomes are vulnerable to Aβ(1-40)-induced oxidative injury
36. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of Aβ1-42
37. Apolipoprotein E modulates Aβ1-42-induced oxidative damage to synaptosomes in an allele-specific manner
38. Regulation of prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions
39. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression
40. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
41. Transition metal mediated glycoxidation accelerates crosslinking of β-amyloid peptide
42. Neuroinflammatory signaling upregulation in Alzheimer's disease
43. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia
44. 2+ homeostasis and cell death
45. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide
46. Oxidative stress hypothesis in Alzheimer's disease
47. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease
48. Apoptosis in neurodegenerative disorders
49. Impairment of membrane transport and signal transduction systems by amyloidogenic proteins
50. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
51. Involvement of beta(2)-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis - Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1
52. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
53. Head trauma as a risk factor for Alzheimer's disease: A collaborative re-analysis of case-control studies: EURODEM Risk Factors Research Group
54. Correlation of astrocytic S100β expression with dystrophic neurites in amyloid plaques of Alzheimer's disease
55. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide
56. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation
57. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappa B activation and cytokine expression
58. Association of interleukin-1 gene polymorphisms with Alzheimer's disease
59. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
60. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain
61. Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions
62. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system
63. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease
64. Free radicals in Alzheimer's disease
65. Clinical trial of indomethacin in Alzheimer's disease
66. Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus
67. Advanced glycation end products in alzheimers-disease and other neurodegenerative diseases
68. Induction of GM-CSF production of macrophages by advanced glycation end products of the Maillard reaction
69. A double-blind placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
70. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
71. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments
72. Amyloid β-protein and the genetics of Alzheimer's disease
73. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: Potential significance for tau protein phosphorylation
74. Interleukin-1 promotes expression and phosphorylation and tau proteins in vivo
75. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis
76. S100β protein expression in Alzheimer's disease: Potential role in the pathogenesis of neuritic plaques
77. Glial-neuronal interactions in Alzheimer's disease: Progressive association of IL-1α microglia and S100β astrocytes with neurofibrillary tangle stages
78. Enlarged and phagocytic, but not primed, IL-1α microglia increase with age in normal human brain
79. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
80. Oxidative posttranslational modifications in Alzheimer disease a possible pathogenic role in the formation of senile plaques and neurofibrillary tangles
81. Alzheimer-disease - DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis
82. Risk of Alzheimer's disease and duration of NSAID use
83. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets
84. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism
85. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain?
86. Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity
87. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's Disease
88. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease
89. A subset of NSAIDs lower amyloidogenic β42 independently of cyclooxygenase activity
90. Overexpression of neuronal cyclooxygenase-2 promotes amyloid (Aβ) deposition in the brain of transgenic mice with Alzheimer's disease type neuropathology
91. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
92. Vitamin E prevents Alzheimer's amyloid β-peptide (1-42)-induced protein oxidation and reactive oxygen species formation
93. Alzheimer's amyloid β-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: Protective effect of vitamin E
94. Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity